Literature DB >> 18312465

Role of Werner syndrome gene product helicase in carcinogenesis and in resistance to genotoxins by cancer cells.

Kazunobu Futami1, Yuichi Ishikawa, Makoto Goto, Yasuhiro Furuichi, Masanobu Sugimoto.   

Abstract

Werner syndrome (WS) is an autosomal recessive genetic disorder causing premature aging, and WRN has been identified as the causative gene of WS. The product of the WRN gene (WRN) acts as a DNA helicase with exonuclease activity, and data have accumulated showing that the WRN gene strongly participates in carcinogenesis: (1) the normal WRN gene likely participates in the immortalization of B-lymphoblastoid cell lines through telomeric crisis caused by telomere shortening, (2) a much higher incidence of rare cancers occurs in WS patients than in other kinds of patients, and (3) levels of WRN expressed in virus-transformed cells and cancer cells are usually markedly up-regulated and are inversely correlated with the sensitivity of these cells against various genotoxins, including camptothecin. In this paper, we review the events that show a close correlation of the WRN gene and WRN with carcinogenesis and their underlying molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312465     DOI: 10.1111/j.1349-7006.2008.00778.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  14 in total

1.  Aging genetics and aging.

Authors:  Sandra Rodríguez-Rodero; Juan Luis Fernández-Morera; Edelmiro Menéndez-Torre; Vincenzo Calvanese; Agustín F Fernández; Mario F Fraga
Journal:  Aging Dis       Date:  2011-04-28       Impact factor: 6.745

2.  WRN, the Werner Syndrome Gene, Exhibits Frameshift Mutations in Gastric and Colorectal Cancers.

Authors:  Ju Hwa Lee; Sung Soo Kim; Min Sung Kim; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2016-12-23       Impact factor: 3.201

3.  Involvement of WRN helicase in immortalization and tumorigenesis by the telomeric crisis pathway (Review).

Authors:  Masanobu Sugimoto; Yasuhiro Furuichi; Toshinori Ide; Makoto Goto
Journal:  Oncol Lett       Date:  2011-05-06       Impact factor: 2.967

4.  Dynamics of the DNA repair proteins WRN and BLM in the nucleoplasm and nucleoli.

Authors:  Kristian Moss Bendtsen; Martin Borch Jensen; Alfred May; Lene Juel Rasmussen; Ala Trusina; Vilhelm A Bohr; Mogens H Jensen
Journal:  Eur Biophys J       Date:  2014-08-14       Impact factor: 1.733

5.  BCR/ABL stimulates WRN to promote survival and genomic instability.

Authors:  Artur Slupianek; Tomasz Poplawski; Stanislaw K Jozwiakowski; Kimberly Cramer; Dariusz Pytel; Ewelina Stoczynska; Michal O Nowicki; Janusz Blasiak; Tomasz Skorski
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

6.  WRN helicase regulates the ATR-CHK1-induced S-phase checkpoint pathway in response to topoisomerase-I-DNA covalent complexes.

Authors:  Birija Sankar Patro; Rikke Frøhlich; Vilhelm A Bohr; Tinna Stevnsner
Journal:  J Cell Sci       Date:  2011-12-08       Impact factor: 5.285

7.  Functional deficit associated with a missense Werner syndrome mutation.

Authors:  Takashi Tadokoro; Ivana Rybanska-Spaeder; Tomasz Kulikowicz; Lale Dawut; Junko Oshima; Deborah L Croteau; Vilhelm A Bohr
Journal:  DNA Repair (Amst)       Date:  2013-04-11

Review 8.  The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis.

Authors:  Meltem Muftuoglu; Junko Oshima; Cayetano von Kobbe; Wen-Hsing Cheng; Dru F Leistritz; Vilhelm A Bohr
Journal:  Hum Genet       Date:  2008-09-23       Impact factor: 4.132

Review 9.  Roles of Werner syndrome protein in protection of genome integrity.

Authors:  Marie L Rossi; Avik K Ghosh; Vilhelm A Bohr
Journal:  DNA Repair (Amst)       Date:  2010-01-13

10.  PLRG1 is an essential regulator of cell proliferation and apoptosis during vertebrate development and tissue homeostasis.

Authors:  André Kleinridders; Hans-Martin Pogoda; Sigrid Irlenbusch; Neil Smyth; Csaba Koncz; Matthias Hammerschmidt; Jens C Brüning
Journal:  Mol Cell Biol       Date:  2009-03-23       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.